Table 2 Comparison of clinical characteristics between group TMP and group TMN during the first visit
Variable | Group TMP (N = 22) | Group TMN (N = 20) | P value |
|---|---|---|---|
Age, years | 52.0 (34.8, 58.0) | 54.5 (29.0, 63.8) | 0.734 |
Male sex, no. (%) | 14 (63.6%) | 13 (65.0%) | 1.0 |
Anti-IFN-γ antibody titer (ng/ml) | 926.31 (760.02, 2103.20) | 332.40 (243.51,491.89) | <0.001 |
Time from symptom onset to diagnosis | 149.5 (57.2, 272.3) | 98.5 (22.3154.5) | 0.107 |
Coexisting respiratory disease, no. (%) | 3 (13.6%) | 10 (50.0%) | 0.019 |
Bronchiolitis | 0 | 4 (20.0%) | 0.043 |
COPD | 2 (9.1%) | 4 (20.0%) | 0.400 |
COPD with bronchiectasis | 0 | 2 (10.0%) | 0.221 |
Asthma | 1 (4.5%) | 0 | 0.476 |
Extrapulmonary organ involvement, no. (%) | 18 (81.8%) | 11 (55.0%) | 0.096 |
Skin | 10 (45.5%) | 3 (15.0%) | 0.047 |
Lymph node | 18 (81.8%) | 11 (55.0%) | 0.096 |
Liver | 2 (9.1%) | 1 (5.0%) | 1.000 |
Spleen | 2 (9.1%) | 0 | 0.489 |
Bone | 9 (40.9%) | 1 (5.0%) | 0.010 |
Symptoms, no. (%) | |||
Fever | 12 (54.5%) | 6 (30.0%) | 0.131 |
Cough | 17 (77.3%) | 17 (85.0%) | 0.700 |
Sputum production | 14 (63.6%) | 15 (75.0%) | 0.514 |
Hemoptysis | 4 (18.2%) | 3 (15.0%) | 1.0 |
Dyspnea | 6 (27.3%) | 3 (15%) | 0.460 |
Chest pain | 9 (40.9%) | 6 (30.0%) | 0.531 |
Osteodynia/Arthralgia | 7 (31.8%) | 3 (15.0%) | 0.284 |
Wasting | 13 (59.0%) | 10 (50.0%) | 0.757 |
Moist rales | 6 (27.3%) | 8 (40.0%) | 0.515 |
Pleural effusion | 13 (59.1%) | 3 (15.0%) | 0.005 |
Co-infection, no. (%) | 12 (55.0%) | 4 (20.0%) | 0.029 |
Outcome, no. (%)a | |||
Cured | 0 | 2 (10.0%) | – |
Improved | 2 (9.1%) | 4 (20.0%) | – |
Ineffective | 6 (27.3%) | 0 | – |
Recurrence | 1 (4.5%) | 0 | – |
Death | 3 (13.6%) | 0 | – |